GSK is the latest to turn its back on prominent industry lobbying group Biotechnology Innovation Organization (BIO), ...

Pacific Trade Invest NZ invites you to an important webinar on the FMCG industry in New Zealand. This will be of great ...

GSK Plc acquired an experimental drug from Chinese biotech firm Chimagen Biosciences for as much as $850 million, adding to ...

GSK’s $2.2 billion Zantac settlement today ... largest ever acquisition with a deal to buy Fantech in Australia and New Zealand. Its performance has been boosted by increasing awareness of ...

GSK (GSK.L), opens new tab has agreed to pay up to $2.2 billion to settle most lawsuits in U.S. state courts claiming that a discontinued version of the heartburn drug Zantac caused cancer ...

GSK (GSK) stock was downgraded by Guggenheim Securities to neutral after the company's Q3 revenue decline. Read more here.

Vaccine maker GSK unveiled new data Tuesday showing its respiratory syncytial virus vaccine Arexvy protected older adults over three seasons against disease caused by infection. Across the entire ...

Investors in GSK plc (Symbol: GSK) saw new options begin trading today, for the May 2025 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time ...

GlaxoSmithKline is under pressure from shareholders ... The launch environment for pharmaceutical industry products is evolving at pace with new scientific discoveries and shifting engagement ...

Wolff Olins has created the new brand identity for global healthcare company GSK (formerly GlaxoSmithKline), aiming to better express its focus on innovation. The agency was brought on board around 18 ...

“Moderna has repeatedly touted the speed at which it produced its original Spikevax vaccine and was later able to modify it to address new viral strains,” GSK said. “But Moderna has ...